Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY accumulated deficit (Tax losses applied to a buyout)

<< Previous

Bullboard Posts

Next >>

Comment by 13X2413on Feb 20, 2024 7:31pm

384 Views

Post# 35889912

RE:RE:RE:RE:RE:RE:RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)

Since I'm not a James Bond operative, I'm dying to know what your message is. What makes your operative like opinion worthy of any more belief than other opinions? In my eyes, the others carry more weight as a result of what the ACTUAL value of the stock has done over the past few months.
I can't take your FAIR value to the bank.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario